<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01295099</url>
  </required_header>
  <id_info>
    <org_study_id>KS001</org_study_id>
    <nct_id>NCT01295099</nct_id>
  </id_info>
  <brief_title>Keloid Scarring: Treatment and Pathophysiology</brief_title>
  <official_title>Keloid Scarring:A Randomized Clinical and Laboratory Based Study on the Treatment and Differentiation Factors of the Local Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen Mary University of London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To clarify the mechanisms of Keloid scar formation.

      Elucidate the action and therapeutic value of 5-FU in Keloid scar treatment

      Identify the genetic link with Keloid scar formation.

      Quantify the psychological/social impact in keloid scarring patients
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Keloid Scar Reduction</measure>
    <time_frame>18 months</time_frame>
    <description>Using a 3D scanner to observe the reduction of the scar volume measured in cubic centimetres</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Keloid</condition>
  <arm_group>
    <arm_group_label>5-Fluorouracil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with small keloidal scars to have intralesional 5FU injected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Large keloid scars undergo extralesional excision and radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5- fluorouracil</intervention_name>
    <description>5mg of 5FU injected per 1cm square, at 6 week intervals for 30 weeks = 6 sessions</description>
    <arm_group_label>5-Fluorouracil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>after complete excision of keloid they have a single session of radiotherapy</description>
    <arm_group_label>Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone</intervention_name>
    <description>TAC 10mg in 1ml injected intralesional</description>
    <arm_group_label>TAC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult ( &gt; 18 years old).

          -  Keloid scarring present.

          -  Able to understand and give informed consent.

          -  Patients giving informed consent to donate keloidal or non-affected skin when that is
             redundant after a procedure (i.e. BBR, Abdominoplasty).

          -  Patients with a strong familial pedigree of keloid scar formation.

        Exclusion Criteria:

          -  Open wound at or proximity of the lesion

               -  Infected lesion

               -  Pregnant or planning pregnancy in the near future

               -  Lactating (Breast Feeding)

               -  Abnormal renal or liver function tests

               -  Atrophic scars

               -  Patient under 18 years of age

               -  Immunocompromised

               -  OR immunosuppressed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Barts and the London NHS Trust</name>
      <address>
        <city>London</city>
        <state>UK</state>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.keloids.co.uk</url>
  </link>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2011</study_first_submitted>
  <study_first_submitted_qc>February 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2011</study_first_posted>
  <last_update_submitted>February 11, 2011</last_update_submitted>
  <last_update_submitted_qc>February 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Simon Myers</name_title>
    <organization>Queen Mary University of London</organization>
  </responsible_party>
  <keyword>scar formation</keyword>
  <keyword>5-FU</keyword>
  <keyword>genetic link</keyword>
  <keyword>psychological impact</keyword>
  <keyword>social impact</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

